Verdict No. 3095 · Search date 2026-09-15 · Methodology v1.0

Oral vitamin B6-only tablets,
does it really help with Reduction of overall symptom severity in diagnosed PMS?

Name: Verdict 3095 · Does vitamin B6 monotherapy reduce overall symptoms in diagnosed PMS?
Creator: Chamgap
Published: 2026-09-15

30-Second Summary

Evidence Grade C · 50 · Safety caution

ChatGPT source review and self-verification · Codex technical integration

Record 127 is a historical related page combining PMS with nausea and vomiting of pregnancy. Its B, 60-point grade and pregnancy evidence are not transferred here. The new page covers overall PMS severity alone and discloses unverified registered outcome hierarchy and exact product details. [L01][S03]

Caution. Trial doses are not dosing instructions. B6 supplements can cause sensory neuropathy, reported below 50 mg/day, and injury may be irreversible. Add up B6 across products; stop the supplement and seek medical advice for tingling, burning or reduced sensation. EFSA adult upper intake of 12 mg/day concerns chronic total intake, not a PMS treatment dose. The Australian pharmacist-only change above 50 through 200 mg/day starts on 2027-06-01 and is still future at the cutoff. No serious events reported in a short trial does not establish long-term neurological safety. Review medicines, supplements and special populations with a clinician; pregnancy safety is not assessed here. [S03][S12][S13][S14][S16]

What the
research showsThere is a signal of improvement, but a reliable treatment benefit is not established. Overall symptom scores favored B6 in placebo-controlled trials using prospective PMS records, but older instruments, missing analysis details and conflicting dose/sample descriptions limit the current evidence to C, 50 points. This is not a verdict on pregnancy nausea or PMDD. [S02][S03]

What the
ads claimThe 9 trials and 940 participants in the 1999 review do not all represent the same B6-only PMS comparison. They include multivitamins and mastalgia-only trials. The B6-only subgroup odds ratio for improvement, 2.15 (confidence interval 1.79–2.59), is not a percentage reduction in total symptom severity or an individual probability of benefit. [S01]

◎

Four separate assessment dimensions

Effect direction and size	There is a signal of improvement, but a reliable treatment benefit is not established. Overall symptom scores favored B6 in placebo-controlled trials using prospective PMS records, but older instruments, missing analysis details and conflicting dose/sample descriptions limit the current evidence to C, 50 points. This is not a verdict on pregnancy nausea or PMDD. [S02][S03]
Evidence certainty	Axes are B/P/R1/I1/E+/B2/CX. Terminal Hedges g=-0.53 is used only for the supplied rubric statistical-magnitude classification, not as a validated between-group clinically important difference. The single main trial family and bias cap yield C; the fixed anchor for 1 strength (E+) is 50 points. No arbitrary additive points or deductions are used. [S03][C08] B2 reflects internally inconsistent participant accounting and insufficiently reproducible total-score construction/normalization. Unverified concealment or registration is not asserted to have been absent.
Applicability	The single claim concerns overall symptom severity in nonpregnant adults with PMS. The main evidence compares two treatment cycles after two diagnostic cycles at ages 18–45; its B6 arm is separate from Hypericum, not a combination. Exact salt and a confirmed daily total dose have not been guessed. [S03]
Safety	Caution. Trial doses are not dosing instructions. B6 supplements can cause sensory neuropathy, reported below 50 mg/day, and injury may be irreversible. Add up B6 across products; stop the supplement and seek medical advice for tingling, burning or reduced sensation. EFSA adult upper intake of 12 mg/day concerns chronic total intake, not a PMS treatment dose. The Australian pharmacist-only change above 50 through 200 mg/day starts on 2027-06-01 and is still future at the cutoff. No serious events reported in a short trial does not establish long-term neurological safety. Review medicines, supplements and special populations with a clinician; pregnancy safety is not assessed here. [S03][S12][S13][S14][S16]

C, 50 is the evidence tier for the fixed overall PMS symptom-improvement claim, not proof of a clinically certain benefit, individual success probability, safety or document quality.

Useful facts when choosing a product

B6 is not one molecular name. Pyridoxine, pyridoxal and PLP are not treated as chemically identical. [S12][S15]
Salt, origin, brand, batch, release form and exact daily total in the key trials are unverified or inconsistently described. Common commercial product information has not been substituted. [S02][S03]
Magnesium+B6, multivitamins, an active comparator containing riboflavin, and PMDD, pregnancy nausea or isolated mastalgia outcomes are separate. [S01][S08][S10]

Chamgap Semantic Classification Code

Permanent code issued

S.vitamin-b6.oral.diagnosed-pms-overall-symptom-severity.improve.placebo

Substances and nutrients > Vitamin B6 monotherapy > Oral > Overall symptom severity in diagnosed PMS > Improvement claim > Placebo

Technically bound to the ChatGPT-fixed comparison of oral vitamin B6 monotherapy over two treatment cycles versus placebo for overall symptom severity in nonpregnant adults with diagnosed PMS. Exact vitamer, salt, daily total dose and registered outcome hierarchy remain unresolved in multidimensional fields. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.

Download semantic index (JSON) · Codebook v1

⌘

Exact Claim Classification

These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.

Intervention class	S · Supplement or nutraceutical
Canonical ingredient or intervention	Vitamin B6 alone; main-trial vitamer and salt unverified
Source or part used	Not verified: manufacturing or biological origin not established
Formulation or processing	Oral tablets; brand, crystal, release and batch unverified
Route	Oral
Dose	Daily total unverified: conflicting tablet-strength wording in main trial; B6 dose unreported in supportive trial
Duration	2 diagnostic cycles followed by 2 treatment cycles; administration throughout the cycle
Population	Nonpregnant adults with PMS, main trial ages 18–45 with prospective symptom diaries; deficiency and detailed PMDD adjudication unverified
Effect or condition	Improvement in overall PMS symptom severity
Primary endpoint	Main trial 12-symptom diary total; registered hierarchy and aggregation range unverified; lower is better
Comparator	Placebo; lactose and cellulose in main trial; fixed common drug regimen unverified
Duplicate-detection key	`Not issued: precise identity contains unresolved facets; not identical to composite claim in 127`

What the research actually shows

Another prospective-diary trial reported B6 36.51 to 22.84 and placebo 35.80 to 28.41. Its arithmetic change contrast of -6.28 points uses a different scale and is not pooled with -3.05 points. Completion counts are 36 for B6 and 37 for placebo, but endpoint-specific analysis denominators were not explicitly verified. B6 dose was not found in the report; 250 mg refers to magnesium. [S02][C05] A separately restored 80 mg/day trial record preserves changes of -1.80 with B6 and -0.93 with placebo; from an initial sample of 160, 94 were analysed. The arithmetic contrast is -0.87 points. These are prior collected values carried in the recovery request; the saved files do not retain the exact original Results location, scale or dispersion. They are not labelled newly primary-verified or used for grading. The 160 are not relabelled randomized and the 94 are not per-arm denominators. [S06][C10]

Why this is classified as C (50)

Axes are B/P/R1/I1/E+/B2/CX. Terminal Hedges g=-0.53 is used only for the supplied rubric statistical-magnitude classification, not as a validated between-group clinically important difference. The single main trial family and bias cap yield C; the fixed anchor for 1 strength (E+) is 50 points. No arbitrary additive points or deductions are used. [S03][C08] B2 reflects internally inconsistent participant accounting and insufficiently reproducible total-score construction/normalization. Unverified concealment or registration is not asserted to have been absent.

Counterpoint. This is not a finding of no effect. Conversely, nominal significance and a statistically medium-sized estimate do not establish clinically important improvement. A formal change-contrast confidence interval, modern instrument validation and sustained long-term benefit remain unverified. [S02][S03]

Rejudgment record. Limited improvement signal with major reporting limitations — Original rubric caps and fixed anchor; clinical importance unverified

Stored scoring profile

Endpoint	P	Symptom or function itself is the target - including patient reports and performance tests
Replication	R1	Single confirmatory trial
Independence	I1	Mixed funding sources
Effect size	E+	Meets the clinically important threshold
Precision	CX	No pooled confidence interval could be confirmed

✓

Review performed and remaining limitations

ChatGPT performed research, source checking, adversarial review and numeric and bilingual self-validation in the same conversation. Codex performed file, schema, collision, build and deployment checks without re-researching the content. This is not external independent review.

Exact vitamer, salt, main-trial daily dose, allocation and analysis flow, total-score normalization, formal change-contrast CI, validated MCID and long-term safety remain unverified. The restored 80 mg/day values were not graded because their original result location was not recovered.

Search scope and limitations. R01-017 verified package: search_log.json; selection_log.json; sources.json

Evidence Table

Study	Design	Sample	Funding	Endpoint	Result	Weight
Ghazanfarpour: B6-only arm versus placebo	Parallel B6-only, Hypericum and placebo arms; only B6 versus placebo contributes to this effect	Table analysis headers: B6 78 and placebo 78; overall recruitment/allocation descriptions conflict	Specific funding and B6 supplier unverified; no-conflict declaration is not proof of independent funding	Total of the 12-symptom diary; lower is better; total normalization unverified	Baseline to end: B6 33.93 to 20.92, placebo 33.86 to 23.90; arithmetic change contrast -3.05 points; formal change CI unverified	Principal evidence, limited by bias/measurement reporting
Ebrahimi: B6-only arm versus placebo	Separate magnesium, B6-only and placebo arms; B6 dose not reported	Allocated 42 per group; completed B6 36 and placebo 37; endpoint denominator unverified	Coded tablets supplied by university pharmacy; funding and author COI unverified	Total of a separate 30-symptom diary; not the main-trial scale	B6 36.51 to 22.84, placebo 35.80 to 28.41; arithmetic change contrast -6.28 points; between-group change CI unverified	Supportive evidence; not pooled across scales
Doll: pyridoxine crossover trial	Pyridoxine 50 mg/day versus placebo; crossover design	Entered 63; 32 completed the full 7 months; endpoint denominators unverified	Funding and COI unverified in accessed abstract	Nine-symptom diary; emotional-domain signal distinguished from whole PMS	Emotional-domain result not transferred to overall symptom improvement	Qualitative, scope-limited evidence
Kendall: pyridoxine study	Pyridoxine 150 mg/day versus placebo	Review reports 55 completers; original endpoint denominator unverified	Unverified; independence not assumed	Mixed domains; original global mean unverified	Global symptom mean and confidence interval not verified	Secondary extraction and limited qualitative evidence
Kashanian: pyridoxine trial and authorship correction	Preserved pyridoxine 80 mg/day versus placebo record; salt and exact formulation unverified	Preserved initial sample of 160 and analysed 94; stage and arm denominators unverified	Funding, product supply and COI unverified; author added by correction in 2020	Values carried as overall PMS change; exact scale and original location not recovered	Preserve -1.80 versus -0.93, arithmetic contrast -0.87; no SD, CI or p value invented	Carry-forward preservation only; not newly primary-verified or used for grading/replication
Retallick-Brown: active-comparator study	Broad-spectrum micronutrients versus B6 comparator; review also describes riboflavin	Not used as a denominator for the fixed B6-only versus placebo effect	Original funding/COI unverified; no independence credit	Modified DRSP not mixed with other scales/comparator contracts	No placebo and strict monotherapy mismatch; excluded from direct effect	Excluded evidence
De Souza: magnesium/B6 material	Separate magnesium, B6, combination and placebo crossover material	Not counted as a new denominator for this overall-severity effect	Unverified	Anxiety domain and overall severity are separate	Combination anxiety result not transferred to B6-only global symptoms	Scope-limited; excluded from direct effect
Fathizadeh: combination study	Magnesium and magnesium+B6 comparisons	Not added as independent B6-only replication participants	Unverified	Not a B6-only global effect	Combination intervention; excluded from direct effect	Excluded; overlap with S02 unverified
Vitagnus/soy study	Vitagnus, soy and combination; no B6 arm	Not counted as B6-effect participants	Funding not separately extracted for excluded study	Not the present B6 endpoint	Excluded as a wrong-intervention search result	Excluded

Receipt — 21 References

Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.

Wyatt et al. 1999. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review

Oral vitamin B6-only tablets,does it really help with Reduction of overall symptom severity in diagnosed PMS?